tetano
Editor, Senior Moderator
Antiviral Res
. 2020 Jul 29;104882.
doi: 10.1016/j.antiviral.2020.104882. Online ahead of print.
An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection
Carina Conzelmann[SUP] 1 [/SUP], Andrea Gilg[SUP] 1 [/SUP], R?diger Gro?[SUP] 1 [/SUP], Desiree Sch?tz[SUP] 1 [/SUP], Nico Preising[SUP] 2 [/SUP], Ludger St?ndker[SUP] 2 [/SUP], Bernd Jahrsd?rfer[SUP] 3 [/SUP], Hubert Schrezenmeier[SUP] 3 [/SUP], Konstantin M J Sparrer[SUP] 1 [/SUP], Thomas Stamminger[SUP] 4 [/SUP], Steffen Stenger[SUP] 5 [/SUP], Jan M?nch[SUP] 6 [/SUP], Janis A M?ller[SUP] 7 [/SUP]
Affiliations
Abstract
SARS-CoV-2 is a novel pandemic coronavirus that caused a global health and economic crisis. The development of efficient drugs and vaccines against COVID-19 requires detailed knowledge about SARS-CoV-2 biology. Several techniques to detect SARS-CoV-2 infection have been established, mainly based on counting infected cells by staining plaques or foci, or by quantifying the viral genome by PCR. These methods are laborious, time-consuming and expensive and therefore not suitable for a high sample throughput or rapid diagnostics. We here report a novel enzyme-based immunodetection assay that directly quantifies the amount of de novo synthesized viral spike protein within fixed and permeabilized cells. This in-cell ELISA enables a rapid and quantitative detection of SARS-CoV-2 infection in microtiter format, regardless of the virus isolate or target cell culture. It follows the established method of performing ELISA assays and does not require expensive instrumentation. Utilization of the in-cell ELISA allows to e.g. determine TCID[SUB]50[/SUB] of virus stocks, antiviral efficiencies (IC[SUB]50[/SUB] values) of drugs or neutralizing activity of sera. Thus, the in-cell spike ELISA represents a promising alternative to study SARS-CoV-2 infection and inhibition and may facilitate future research.
Keywords: Antiviral testing; Drug screening; In-cell ELISA; Neutralization; SARS-CoV-2.
. 2020 Jul 29;104882.
doi: 10.1016/j.antiviral.2020.104882. Online ahead of print.
An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection
Carina Conzelmann[SUP] 1 [/SUP], Andrea Gilg[SUP] 1 [/SUP], R?diger Gro?[SUP] 1 [/SUP], Desiree Sch?tz[SUP] 1 [/SUP], Nico Preising[SUP] 2 [/SUP], Ludger St?ndker[SUP] 2 [/SUP], Bernd Jahrsd?rfer[SUP] 3 [/SUP], Hubert Schrezenmeier[SUP] 3 [/SUP], Konstantin M J Sparrer[SUP] 1 [/SUP], Thomas Stamminger[SUP] 4 [/SUP], Steffen Stenger[SUP] 5 [/SUP], Jan M?nch[SUP] 6 [/SUP], Janis A M?ller[SUP] 7 [/SUP]
Affiliations
- PMID: 32738255
- DOI: 10.1016/j.antiviral.2020.104882
Abstract
SARS-CoV-2 is a novel pandemic coronavirus that caused a global health and economic crisis. The development of efficient drugs and vaccines against COVID-19 requires detailed knowledge about SARS-CoV-2 biology. Several techniques to detect SARS-CoV-2 infection have been established, mainly based on counting infected cells by staining plaques or foci, or by quantifying the viral genome by PCR. These methods are laborious, time-consuming and expensive and therefore not suitable for a high sample throughput or rapid diagnostics. We here report a novel enzyme-based immunodetection assay that directly quantifies the amount of de novo synthesized viral spike protein within fixed and permeabilized cells. This in-cell ELISA enables a rapid and quantitative detection of SARS-CoV-2 infection in microtiter format, regardless of the virus isolate or target cell culture. It follows the established method of performing ELISA assays and does not require expensive instrumentation. Utilization of the in-cell ELISA allows to e.g. determine TCID[SUB]50[/SUB] of virus stocks, antiviral efficiencies (IC[SUB]50[/SUB] values) of drugs or neutralizing activity of sera. Thus, the in-cell spike ELISA represents a promising alternative to study SARS-CoV-2 infection and inhibition and may facilitate future research.
Keywords: Antiviral testing; Drug screening; In-cell ELISA; Neutralization; SARS-CoV-2.